<document>

<filing_date>
2020-04-02
</filing_date>

<publication_date>
2020-10-08
</publication_date>

<priority_date>
2019-04-03
</priority_date>

<ipc_classes>
C12Q1/04,C12Q1/689
</ipc_classes>

<assignee>
4D PHARMA CORK LIMITED
</assignee>

<inventors>
JEFFERY, IAN
O'TOOLE, PAUL
SHANAHAN, FERGUS
O'HERLIHY, Eileen
DAS, Anubhav
</inventors>

<docdb_family_id>
70057152
</docdb_family_id>

<title>
METHODS OF DIAGNOSING DISEASE
</title>

<abstract>
The application provides new and improved methods for diagnosing BAM.
</abstract>

<claims>
1. A method of diagnosing bile acid malabsorption (BAM) in a patient comprising detecting: a. a bacterial strain of a taxa associated with BAM; or
b. a metabolite associated with BAM.
2. The method of claim 1 wherein the method comprises detecting a bacterial strain of a taxa associated with BAM and a metabolite associated with BAM.
3. The method of claim 1 or claim 2, wherein the bacterial strain is of a family selected from the list consisting of: Lachnospiraceae, Bacteroidaceae, Ruminococcaceae,
Bifidobacteriaceae, Prevotellaceae, Veillonellaceae and Coriobacteriaceae .
4. The method of claim 1 or claim 2, wherein the bacterial strain is of a genus selected from the list consisting of: Blautia, Bacteroides, Faecalibacterium, Oscillibacter,
Ruminococcus, Bifidobacterium, Coprococcus, Paraprevotella, Gemmiger, Dialister, Megamonas and Butyricicoccus.
5. The method of claims 2-4, wherein the bacterial strain belongs to an operational taxonomic unit (OTU) selected from table 2 and/or table 5.
6. The method of claim 1 or claim 2, wherein the bacterial strain has a 16S rRNA gene
sequence at least 97% identical to one of SEQ ID NO: 1-38.
7. The method of any one of claims 1-6, wherein strains of 2, 5, 10, 15 or 20 bacterial taxa are detected.
8. The method of claim 1 or claim 2, wherein the metabolite is selected from the group
consisting of: PG(P- 16: 0/14:0), 2-Ethylsuberic acid, Glu-Glu-Gly-Tyr, 1,2,3-Tris(lethoxyethoxy)propane, PG(O-30: l), Ursodeoxycholic acid, MG(22:2(13Z,16Z)/0: 0/0:0), LLysine, O-Phosphoethanolamine, PE(22:5(7Z,10Z,13Z,16Z,19Z)/24:0) and Heptadecanoic acid.
9. The method of claim 1 or claim 2, wherein the metabolite is selected from the group
consisting of: 1,3-di-(5Z,8Z,l lZ,14Z,17Z-eicosapentaenoyl)-2-hydroxy-glycerol (d5), Dimethyl benzyl carbinyl butyrate, l-18:0-2-18:2-monogalactosyldiacylglycerol, PG(P- 16:0/14:0), Glu-Glu-Gly-Tyr, PC(22:2(13Z,16Z)/15:0), PG(34:0), PE(18:3(6Z,9Z,12Z)/P- 18:0), MG(22:2(13Z,16Z)/0: 0/0:0), Arg-Ile-Gln-Ile" PE(22:5(7Z,10Z,13Z,16Z,19Z)/24:0), PC(18: 1(9Z)/15:0), Thiophanate-methyl, Asn-Ser-His-His, 1,2,3-Tris(lethoxyethoxy)propane, PS(39:6), 2-Hydroxylauroylcamitine, Hypoxanthine, Adenosine, PC(40:6), Asp-Phe-Phe-Val, 3-Dehydroxycamitine, Inosine, PG(0-34:3), 11- Deoxocucurbitacin I, Methyl caprate, Linoleoyl ethanolamide, His-Met-Phe-Phe, 1- Decanol, Gravelliferone, Uridine, Arachidyl carnitine, Guanosine, Methyl nonylate, 3- Epidemissidine, Momordol, N-[2-(lH-Indol-3-yl)ethyl]docosanamide, Methyl caproate, Ascorbic acid, N-Acetyl-leu-leu-tyr, 4-Hydroxybutyric acid, [ST dimethyl(4: 0/3:0)] (5Z,7E, 17Z)-( 1 S,3R)-26,27-dimethyl-9, 10-seco-5 ,7, 10( 19), 17(20)-cholestatetraen-22-yne- 1,3,25-triol, N-Methylindolo[3,2-b]-5alpha-cholest-2-ene and gamma-Glutamyl-Smethy ley steinyl -beta-alanine .
10. The method of claim 1 or claim 2, wherein the metabolite is selected from the group
consisting of: PG(P- 16: 0/14:0), 2-Ethylsuberic acid, Glu-Glu-Gly-Tyr, 1,2,3-Tris(lethoxyethoxy)propane, PG(O-30: l), Ursodeoxycholic acid, MG(22:2(13Z,16Z)/0: 0/0:0), LLysine, O-Phosphoethanolamine, PE(22:5(7Z,10Z,13Z,16Z,19Z)/24:0), Heptadecanoic acid, 1,3-di-(5Z,8Z,HZ,14Z,17Z-eicosapentaenoyl)-2-hydroxy-glycerol (d5), Dimethyl benzyl carbinyl butyrate, 1- 18:0-2-18 :2-monogalactosyldiacylglycerol,
PC(22:2(13Z,16Z)/15:0), PG(34:0), PE(18:3(6Z,9Z,12Z)/P-18:0), Arg-Ile-Gln-Ile, PC(18: 1(9Z)/15:0), Thiophanate-methyl, Asn-Ser-His-His, PS(39:6), 2- Hydroxylauroylcamitine, Hypoxanthine, Adenosine, PC(40:6), Asp-Phe-Phe-Val, 3- Dehydroxycamitine, Inosine, PG(0-34:3), 11-Deoxocucurbitacin I, Methyl caprate, Linoleoyl ethanolamide, His-Met-Phe-Phe, 1-Decanol, Grave lliferone, Uridine, Arachidyl carnitine, Guanosine, Methyl nonylate, 3-Epidemissidine, Momordol, N-[2-(lH-Indol-3- yl)ethyl]docosanamide, Methyl caproate, Ascorbic acid, N-Acetyl-leu-leu-tyr, 4- Hydroxybutyric acid, [ST dimethyl(4: 0/3:0)] (5Z,7E,17Z)-(lS,3R)-26,27-dimethyl-9,10- seco-5,7,10(19),17(20)-cholestatetraen-22-yne-1,3,25-triol, N-Methylindolo[3,2-b]-5alphacholest-2-ene and gamma-Glutamyl-S-methylcysteinyl-beta-alanine.
11. The method of any of claims 1-10, wherein the method is for diagnosing severe BAM.
12. The method of any of claims 1-11, wherein the patient has previously been diagnosed as suffering from IBS, anorexia nervosa or inflammatory bowel disease, e.g. ulcerative colitis or Crohn's disease.
13. A kit comprising reagents for performing the method of any of the preceding claims.
14. A kit comprising reagents for detecting two or more of the bacterial strains defined in
claims 2-6, and/or the metabolites defined in claim 8.
15. The kit of claim 13 or 14 configured to analyse a fecal sample.
</claims>
</document>
